REVELATION BIOSCIENCES, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
REVELATION BIOSCIENCES, INC. (REVB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $740.92 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-26
- REVELATION BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- REVELATION BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- REVELATION BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-06-30 was $0.00.
- REVELATION BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $67.34K.
- REVELATION BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $740.92K.
- REVELATION BIOSCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $67.34K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $740.92K 10-K · filed 2026-02-26 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $67.34K 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $67.34K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $67.34K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $67.34K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |